Famomax50 ml

Famomax is a histamine H2-receptor antagonist used to reduce gastric acid secretion. Its established, evidence-based uses include:

FDA-approved / established indications

• Active duodenal ulcer - short-term treatment and maintenance therapy at reduced dosage to prevent recurrence.
• Active benign gastric ulcer - short-term treatment.
• Gastroesophageal reflux disease (GERD) - relief of symptomatic, non-erosive disease (heartburn) and treatment of erosive esophagitis.
• Pathological hypersecretory conditions such as Zollinger-Ellison syndrome, either alone or as an adjunct to other therapy.

Commonly accepted additional uses

• Relief of heartburn, acid indigestion, and sour stomach (over-the-counter strength, short-term, symptomatic relief).
• Prevention of exercise-induced or meal-induced heartburn when taken before eating.
• Adjunct in stress ulcer prophylaxis in critically ill patients (guideline/off-label use, typically hospital-directed).

Famomax does not cure the underlying acid-related disorder; it controls symptoms and promotes healing while the underlying condition is managed.

Each tablet/dose typically contains Famotidine as the active pharmaceutical ingredient, commonly available in strengths of 10 mg, 20 mg, and 40 mg tablets, as an oral suspension (e.g., 40 mg/5 mL after reconstitution), and as an injectable solution (e.g., 10 mg/mL or 20 mg/2 mL) for intravenous use. Tablets and suspensions also contain standard inactive excipients such as binders, fillers, and coating agents, which vary by manufacturer and formulation.

Famomax is a competitive, reversible histamine H2-receptor antagonist that decreases the amount of acid produced by the stomach. It belongs to the same pharmacological class as cimetidine, ranitidine, and nizatidine, but is more potent on a milligram basis and has a longer duration of action.

Famomax is used both as a prescription medicine for peptic ulcer disease and GERD, and in lower-strength over-the-counter formulations for the relief of heartburn and acid indigestion. It is available as oral tablets, oral suspension, and intravenous injection for patients who cannot take oral medication.

Famomax belongs to the therapeutic class of Histamine H2-receptor antagonists (H2 blockers), a group of medicines used to reduce gastric acid secretion in the treatment of acid-related disorders of the upper gastrointestinal tract.

Famotidine is a competitive antagonist at histamine H2-receptors located on the basolateral membrane of gastric parietal cells. By blocking these receptors, Famotidine inhibits histamine-stimulated gastric acid secretion, and also reduces basal, nocturnal, and food-, caffeine-, and pentagastrin-stimulated acid secretion, with a lesser effect on gastric acid volume and pepsin output.

Famotidine is rapidly but incompletely absorbed after oral administration (bioavailability approximately 40-45%), with an onset of action within 1 hour and a duration of action of 10-12 hours after a single dose. It undergoes minimal hepatic metabolism, is primarily eliminated renally (both by glomerular filtration and tubular secretion), and has a plasma elimination half-life of approximately 2.5-4 hours in patients with normal renal function; this half-life is prolonged in renal impairment.

Famomax tablets and oral suspension may be taken with or without food. For once-daily dosing, it is generally taken at bedtime; for twice-daily dosing, it is taken in the morning and at bedtime. The oral suspension should be shaken well before each use and measured with an accurate measuring device. The injectable form is administered by a healthcare professional via slow intravenous injection or infusion, generally reserved for patients unable to take oral medication.

Famomax does not significantly interact with the cytochrome P450 hepatic enzyme system, so it has fewer clinically significant drug interactions than some other acid-reducing agents. However, the following interactions are clinically relevant:

• pH-dependent absorption drugs: By raising gastric pH, Famomax can reduce the absorption and effectiveness of drugs that require an acidic environment for absorption, such as certain antifungals (e.g., ketoconazole, itraconazole), certain antiretrovirals (e.g., atazanavir, rilpivirine, delavirdine), cefditoren, and dasatinib. Separating dosing times or using alternative therapy may be necessary.
• Tizanidine: Concomitant use may substantially increase tizanidine blood concentrations, increasing the risk of hypotension and sedation; concurrent use should generally be avoided.
• Probenecid: May decrease renal clearance of Famomax, increasing its plasma concentration.
• Antacids: May be co-administered, though separating doses is sometimes recommended to avoid altering the absorption profile of certain formulations.

Famomax is generally well tolerated. Most side effects are mild and transient.

Common side effects

• Headache
• Dizziness
• Constipation
• Diarrhea
• Nausea and vomiting
• Dry mouth

Less common / rare side effects

• Fatigue and drowsiness, or insomnia
• Confusion, agitation, hallucinations, or other CNS effects (mainly in elderly patients or those with renal impairment - see Precautions)
• Rash or itching
• Tachycardia or palpitations
• Rare hematologic effects (e.g., thrombocytopenia)
• Rare severe skin reactions (e.g., Stevens-Johnson syndrome) or anaphylaxis

Patients should seek prompt medical attention for signs of a severe allergic reaction (swelling of the face/throat, difficulty breathing, severe rash) or unusual symptoms such as severe confusion.

Pregnancy: Animal reproduction studies have not shown evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Famomax should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. A physician should always be consulted before use during pregnancy.

Lactation: Famomax is excreted in human breast milk. Because of the potential for effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue Famomax, taking into account the importance of the drug to the mother, in consultation with a physician.

• Gastric malignancy: Symptomatic response to Famomax does not exclude the presence of gastric malignancy. In adults with new-onset dyspepsia or gastric ulcer, especially those over 50 years or with alarm symptoms (weight loss, recurrent vomiting, dysphagia, GI bleeding), gastric malignancy should be excluded before starting therapy, as Famomax may mask symptoms and delay diagnosis.
• Renal impairment: Dose reduction is required (see Dosage and Administration), as accumulation increases the risk of CNS adverse effects.
• Elderly patients: Increased risk of CNS effects such as confusion, agitation, disorientation, or hallucinations, particularly when renal function is also reduced; dose adjustment and monitoring are advised.
• QT interval prolongation: Has been reported rarely, primarily in patients with moderate-to-severe renal impairment; caution is advised in patients with pre-existing QT prolongation or on other QT-prolonging drugs.
• Rebound acid hypersecretion: May occur on abrupt discontinuation after prolonged use, though this is generally less pronounced than with proton pump inhibitors; gradual dose tapering may be considered after long-term therapy.
• Long-term use: Unlike proton pump inhibitors, Famomax is not strongly associated with fracture risk, vitamin B12 deficiency, or magnesium deficiency, but routine long-term use should still be under medical supervision.

Symptoms of Famomax overdose may include confusion, drowsiness, dizziness, hypotension, and transient adverse effects similar to those seen at therapeutic doses, though they are typically not life-threatening. In case of a suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is generally symptomatic and supportive; unabsorbed material may be removed from the gastrointestinal tract by standard measures under medical supervision, and hemodialysis may be considered in severe cases, particularly with renal impairment, since Famomax is efficiently removed by dialysis. Do not attempt to manage an overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Reconstituted oral suspension should be stored as directed on the label (typically at room temperature) and discarded after 30 days.

• Renal impairment: Dose reduction or extended dosing intervals are necessary (see Dosage and Administration), as Famomax is primarily eliminated by the kidneys and accumulation increases the risk of CNS side effects.
• Hepatic impairment: No specific dosage adjustment is generally required, as Famomax undergoes minimal hepatic metabolism; use with routine caution.
• Elderly: No dosage adjustment is required based on age alone, but elderly patients (especially those with reduced renal function) are at increased risk of CNS adverse effects and should be monitored closely.
• Pediatric patients: Use as per weight-based dosing guidance (see Pediatric Uses); safety and efficacy in neonates and infants below 3 months of age for indications beyond GERD have not been well established.
• Pregnancy and lactation: See "Pregnancy and Lactation" section above.

Duration of Famomax therapy depends on the condition being treated: typically up to 6-8 weeks for active ulcers and non-erosive GERD, and up to 12 weeks for erosive esophagitis. Maintenance therapy at a lower dose may be continued longer term for prevention of ulcer recurrence, as directed by a physician. For self-treatment of occasional heartburn (OTC use), Famomax should not be used continuously for more than 2 weeks without consulting a doctor.

The oral powder for suspension formulation of Famomax (40 mg/5 mL) must be reconstituted with purified water before use, according to the manufacturer's instructions printed on the bottle label. After adding the specified amount of water, the bottle should be shaken vigorously to ensure the powder is fully suspended. The reconstituted suspension should be shaken well before each dose, stored as directed (typically at room temperature, protected from light), and any unused portion discarded after 30 days.

Histamine H2-receptor antagonist (H2 blocker); Anti-ulcer / gastric acid secretion inhibitor.

Famotidine works by selectively and competitively blocking histamine at the H2-receptors of gastric parietal cells. Since histamine is a key mediator that stimulates acid secretion (via the enzyme H+/K+-ATPase pathway indirectly through cyclic AMP), blocking the H2-receptor reduces both the volume and acid concentration of gastric secretions, including basal (fasting) acid output and acid stimulated by food, caffeine, insulin, and pentagastrin. This leads to a sustained rise in intragastric pH, allowing healing of acid-related mucosal damage and symptom relief.

Category B (legacy FDA pregnancy classification, prior to the 2015 Pregnancy and Lactation Labeling Rule)

Famomax is approved for use in pediatric patients for GERD and related acid-related conditions, with dosing based on age and body weight:

Pediatric doses of Famomax should always be determined and supervised by a pediatrician, as safety and efficacy have not been established for all indications and all age groups.